Literature DB >> 10451488

Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.

M F Evans1, I W McDicken, C S Herrington.   

Abstract

The clinical behaviour of ovarian tumours of low malignant potential (LMP) is unpredictable and it has been suggested that the majority of these lesions have no invasive potential. This study has analysed 92 epithelial ovarian tumours [11 mucinous cystadenomas, 18 mucinous LMP tumours, 15 mucinous carcinomas (9 FIGO stage I), 16 serous cystadenomas, 15 serous LMP tumours, and 17 serous carcinomas (11 FIGO stage I)] for numerical abnormalities of chromosomes 1, 11, 17, and X by interphase cytogenetics. Overall, numerical aberrations were identified in none of the cystadenomas, 15 per cent of serous LMP tumours, 17 per cent of mucinous LMP tumours, 67 per cent of mucinous carcinomas, and 82 per cent of invasive serous carcinomas. In mucinous LMP tumours, chromosome gains were associated with spindled nuclear morphology. Chromosome abnormalities were significantly more frequent in invasive mucinous (overall p< 0.01; stage I p< 0.05) and serous (overall p< 0.001; stage I p< 0.01) carcinomas than in the corresponding LMP tumours. No significant relationship between either stromal invasion or tumour type and the pattern of chromosome loss or gain was identified, although monosomy X was identified almost exclusively in invasive serous carcinomas. These observations are consistent with the concept that LMP tumours are unlikely to be precursors of ovarian carcinoma, but suggest that chromosome instability is important in the development of the invasive phenotype. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  1999        PMID: 10451488     DOI: 10.1002/(SICI)1096-9896(199909)189:1<53::AID-PATH393>3.0.CO;2-U

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas.

Authors:  Rong Wu; Lin Lin; David G Beer; Lora H Ellenson; Barbara J Lamb; Jean-Marie Rouillard; Rork Kuick; Samir Hanash; Donald R Schwartz; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

2.  Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin.

Authors:  V S Dhillon; A R Young; S A Husain; M Aslam
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

3.  The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.

Authors:  Signe Penner-Goeke; Zelda Lichtensztejn; Megan Neufeld; Jennifer L Ali; Alon D Altman; Mark W Nachtigal; Kirk J McManus
Journal:  PLoS Genet       Date:  2017-04-04       Impact factor: 5.917

Review 4.  Ovarian tumors of low malignant potential.

Authors:  E L Trimble; C L Trimble
Journal:  Curr Treat Options Oncol       Date:  2001-04

5.  BRCA1-mediated repression of select X chromosome genes.

Authors:  Amir A Jazaeri; Gadisetti VR Chandramouli; Olga Aprelikova; Ulrike A Nuber; Christos Sotiriou; Edison T Liu; H Hilger Ropers; Cindy J Yee; Jeff Boyd; J Carl Barrett
Journal:  J Transl Med       Date:  2004-09-21       Impact factor: 5.531

6.  Genome profiling of ovarian adenocarcinomas using pangenomic BACs microarray comparative genomic hybridization.

Authors:  Donatella Caserta; Moncef Benkhalifa; Marina Baldi; Francesco Fiorentino; Mazin Qumsiyeh; Massimo Moscarini
Journal:  Mol Cytogenet       Date:  2008-05-20       Impact factor: 2.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.